Study on the Safety and Effectiveness of Favezelimab and Pembrolizumab for Blood Cancers

Inclusion Criteria

• Have at least one tumor that can be measured accurately using scans like CT or MRI, with specific size requirements.
• Be able to provide a tumor sample for analysis, either from a recent biopsy or a new one at the start of the study.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.

Exclusion Criteria

• Have active cancer in the brain or spinal cord.
• Have previously received certain types of cancer treatments, such as LAG-3 antibodies or CAR-T-cell therapy, for specific blood cancers.
• Have had cancer treatment or chest radiation within 14 days before starting the study treatment.
• Have significant side effects from previous treatments that have not improved.
• Have received a monoclonal antibody treatment within 4 weeks before the study or have not recovered from its side effects.
• Have received a live vaccine within 30 days before starting the study treatment.
• Have used an experimental drug or device within 4 weeks before starting the study.
• Have an immune system deficiency or are on long-term steroid or immunosuppressive therapy.
• Have another active cancer that needs treatment, except for certain skin cancers or cervical cancer that has been treated.
• Have an autoimmune disease that needed treatment in the past 2 years.
• Have a history of lung inflammation that needed steroids or have current lung inflammation.
• Have an active infection needing IV treatment.
• Have a history of HIV, active hepatitis B, or hepatitis C.
• Are pregnant, breastfeeding, or planning to have children during the study and for 120 days after the last treatment.
• Have had a stem cell or organ transplant in the last 5 years.